Explore groundbreaking studies, clinical trial updates, and emerging technologies shaping the future of cancer treatment.
Breakthrough research on zenocutuzumab, a bispecific antibody targeting NRG1 fusion-positive cancers, with results from the eNRGy trial showing promising outcomes across multiple tumor types.